Liver Transplant Survival Rates
Patients with alcohol-associated liver disease who received a liver transplant lived roughly 45 percent longer than those who did not, according to a large national study published in Alcohol: Clinical and Experimental Research, News-Medical reported.
The research team tracked commercial insurance and Medicare Advantage claims for more than 370,000 patients diagnosed with alcohol-associated liver disease between 2017 and 2024. Out of that large group, roughly 3,500 individuals underwent liver transplantation during the study window.
Survival Differences Over Time
Over the first eight years following a diagnosis, transplant recipients lived an average of 7.1 years. Patients who did not receive a transplant survived an average of 4.9 years over the same timeframe.
The observational analysis estimated average survival times at three, five, and eight years post-diagnosis. Transplant recipients demonstrated a 63 percent lower adjusted risk of death across the evaluated periods.
Because transplant recipients were generally younger and presented with fewer health complications initially, the study authors adjusted for these variables. The findings show an association rather than proof that the surgery alone caused the extended lifespan.
Disparities in Transplant Access
Data showed inconsistencies in tracking which patients received donor organs. Women and African Americans faced lower odds of obtaining a transplant despite having no higher underlying risk of death than men or White patients.
Patients diagnosed with non-metastatic liver cancer, liver decompensation symptoms, and alcohol-associated cirrhosis experienced increased odds of receiving a transplant. Conversely, individuals with a formal medical record of alcohol use disorder held less than half the odds of receiving the procedure.
These clinical conditions also correlated with a higher risk of death. That pattern likely points toward delayed medical referrals or advanced disease states at the time of initial evaluation.
Frequently Asked Questions
Why did the study follow patients from diagnosis instead of the transplant date?
Most previous research started tracking patient outcomes only after a transplant occurred. This study tracked individuals from their initial diagnosis to capture the critical period when many patients grow sicker or die while awaiting an organ.
How large was the patient cohort in the research?
The study analyzed national insurance claims data for more than 370,000 commercially insured and Medicare Advantage patients diagnosed with alcohol-associated liver disease from 2017 to 2024.
What factors did researchers adjust for in their analysis?
The authors adjusted for differences in age, overall health status, liver disease severity, and pre-existing medical conditions present in the ten years prior to the initial diagnosis.
Worth a look